XANTHORRHIZOL
XANTHORRHIZOL Basic information
- Product Name:
- XANTHORRHIZOL
- Synonyms:
-
- XANTHORRHIZOL
- 2-methyl-5-[(2R)-6-methylhept-5-en-2-yl]phenol
- 5-(1,5-Dimethyl-4-hexenyl)-2-methylphenol
- o-Cresol, 5-(1,5-dimethyl-4-hexenyl)-, (-)-
- Phenol, 5-(1,5-dimethyl-4-hexenyl)-2-methyl-, (R)-
- (R)-5-(1,5-dimethyl-4-hexenyl)-o-cresol
- Xanthorrhizol from Cucuma xanthorrhiza
- (R)-Xanthorrizol
- CAS:
- 30199-26-9
- MF:
- C15H22O
- MW:
- 218.33
- EINECS:
- 250-090-2
- Mol File:
- 30199-26-9.mol
XANTHORRHIZOL Chemical Properties
- Boiling point:
- 326.9±11.0 °C(Predicted)
- Density
- 0.948±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- solubility
- Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
- form
- Colorless to light yellow oil.
- pka
- 10.34±0.10(Predicted)
- color
- Pale Yellow to Light Yellow
- LogP
- 5.480
Safety Information
- Hazard Codes
- T
- Risk Statements
- 60
- Safety Statements
- 53-36/37/39-45
XANTHORRHIZOL Usage And Synthesis
Uses
Xanthorrhizol is a nautral sesquiterpenoid from the rhizome of Curcuma xanthorrhiza that induces apoptosis and growth arrest in HCT116 human colon cancer cells.
Definition
ChEBI: Xanthorrhizol is a sesquiterpenoid.
in vivo
Ear edema induced by the topical application of TPA is suppressed by pre-treatment with Xanthorrhizol in a doserelated manner (P<0.005). Topical application of Xanthorrhizol alone does not induce ear edema in mice. All the mice treated with 7.5 nM TPA for 19 weeks after initiation by DMBA developed an average of 15.5±2.3 skin tumors per mouse (tumor multiplicity). Pre-treatment with 2 and 6 μM Xanthorrhizol reduces tumor multiplicity to 6.9±1.1 (P<0.005) and 4.0±1.1 (P<0.005), respectively, at 19 weeks. In addition, Xanthorrhizol at 2 and 6 μM dose dependently lowers the percentage of tumor-bearing mice (tumor incidence) to 80 and 57%, respectively, at the termination of the experiments. Furthermore, the tumor multiplicity (P<0.05) and incidence are reduced in the DMBA-initiated mice that are topically treated with Xanthorrhizol for 6 weeks after the induction of papillomas with hyperplasia, mild dysplasia and moderate dysplasia by topical TPA application for 6, 18 and 24 weeks, respectively. The increased ODC expression in mouse epidermis with acute inflammation and tumor promotion induced by TPA is inhibited by pre-treatment with Xanthorrhizol in a dose-dependent manner. The topical application of Xanthorrhizol after the induction of papillomas with hyperplasia and dysplasia also potently inhibited ODC expression[3].
storage
+4°C
XANTHORRHIZOLSupplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 021-51320588
- tauto@tautobiotech.com
- Tel
- 0755-0755-66853366 13670046396
- sales@chem-strong.com
- Tel
- +86-21-61263340; 17609490614 13764994101
- fisherwang@glschina.com
XANTHORRHIZOL(30199-26-9)Related Product Information
- 4-[(1R)-1,5-Dimethyl-4-hexen-1-yl]-6-hydroxy-2-cycloehexen-1-one
- Xanthone Impurity 9
- 2-Deoxy-D-xylose
- 9H-Xanthen-9-one, 2-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]-1,3,6,7-tetrahydroxy-
- XANTHOTOXOL
- Xanthophyll
- L-xylulose
- Xanthone Impurity 11
- D-[2-2H]XYLOSE
- 3-Morpholinopropanol
- [5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[hydroxy-(3,4,5-trihydroxyoxan-2-yl)oxy-phosphoryl]oxy-phosphinic acid
- 4-[(1R)-1,5-Dimethyl-4-hexen-1-yl]-2-cyclohexen-1-one
- 5-[(1R)-1,5-Dimethyl-4-hexen-1-yl]-2-methyl-3-cyclohexene-1,1-diol
- 5H-Furo[3,2-b]xanthene-2-carboxylic acid, 2,3-dihydro-11-methyl-5-oxo-
- 7-ACETYLLYCOPSAMINE
- Benzene, 4-[(1S)-1,5-dimethyl-4-hexen-1-yl]-2-methoxy-1-methyl-
- 1H-Benzimidazole, 1-(1-oxo-2-propenyl)-2-(4-thiazolyl)-
- D-Xylose, 5-deoxy-